Defining optimal antithrombotic therapy post-TAVI: the contribution of ATLANTIS
Eur Heart J
.
2022 Aug 1;43(29):2798-2800.
doi: 10.1093/eurheartj/ehac139.
Authors
Felicita Andreotti
1
,
Massimo Massetti
1
,
Jurrien Ten Berg
2
3
Affiliations
1
Department of Cardiovascular Sciences, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
2
Department of Cardiology and Center for Platelet Function Research, St Antonius Hospital, Nieuwegein, The Netherlands.
3
Cardiovascular Research Institute Maastricht (CARIM), Maastricht, The Netherlands.
PMID:
35583144
DOI:
10.1093/eurheartj/ehac139
No abstract available
Publication types
Editorial
Comment
MeSH terms
Aortic Valve Stenosis* / surgery
Fibrinolytic Agents / therapeutic use
Humans
Pyrazoles
Pyridones
Standard of Care
Transcatheter Aortic Valve Replacement*
Substances
Fibrinolytic Agents
Pyrazoles
Pyridones
apixaban